Key result
Transcatheter, intramyocardial injection of autologous bone marrow progenitor cells decreased end diastolic volume from 208.7 to 167.4 mL at 1 year (P=0.03).
Why the study?
Does transendocardial, intramyocardial injection of autologous bone marrow progenitor cells improve functional recovery and reverse remodeling in patients with ischemic cardiomyopathy?
Cohort (n=8)
Does transendocardial, intramyocardial injection of autologous bone marrow progenitor cells improve functional recovery and reverse remodeling in patients with ischemic cardiomyopathy?
p-value: p=0.03
Transcatheter intramyocardial injection of autologous bone marrow progenitor cells appears safe and is associated with improved regional contractility and reverse remodeling in patients with ischemic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Should not change practice; hypothesis-generating for cell therapy in ischemic cardiomyopathy.
Williams et al. (2011) conducted a cohort in Ischemic cardiomyopathy (n=8). Transendocardial, intramyocardial injection of autologous bone marrow progenitor cells was evaluated on End diastolic volume (p=0.03). Transcatheter, intramyocardial injection of autologous bone marrow progenitor cells decreased end diastolic volume from 208.7 to 167.4 mL at 1 year (P=0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: